Tony S K Mok
Overview
Explore the profile of Tony S K Mok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
7764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li M, Mok K, Chan L, Mok T
J Liq Biopsy
. 2025 Mar;
3:100131.
PMID: 40026566
Molecular profiling is essential for treatment of patients with advanced non-small cell lung cancer. Extensive evidence supports the clinical application of liquid biopsy in molecular profiling and thus has been...
2.
Wong W, Mok K, Tsui G, Chen O, Loong H, Chan L, et al.
Clin Lung Cancer
. 2025 Feb;
PMID: 39933981
Background: Central nervous system (CNS) metastases are common among patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC). Osimertinib in combination with chemotherapy beyond osimertinib...
3.
Janne P, Wang B, Cho B, Zhao J, Li J, Hochmair M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401269.
PMID: 39879577
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III...
4.
Liu G, Nyaw S, Mok T, Curcio H, Cortot A, Kam T, et al.
Cancer Med
. 2025 Jan;
14(3):e70369.
PMID: 39861957
Background: Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes....
5.
Saw S, Zhong W, Fu R, Li M, Goto Y, Fox S, et al.
Lung Cancer
. 2025 Jan;
200:108076.
PMID: 39799810
The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy....
6.
Li M, Chan A, Mok K, Chan L, Mok T
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241302021.
PMID: 39649017
Adoption of immunotherapy has completely transformed the treatment landscape of cancer. Patients with advanced cancer treated with immunotherapy may benefit from durable tumor response and long-term survival. The most widely...
7.
Solomon B, Liu G, Felip E, Mok T, Soo R, Mazieres J, et al.
Future Oncol
. 2024 Oct;
20(40):3377-3387.
PMID: 39360949
What Is This Study About?: This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines...
8.
Pu X, Li J, Zhang B, Zhang J, Mok T, Nakagawa K, et al.
Future Oncol
. 2024 Oct;
20(37):2971-2982.
PMID: 39360943
We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with -positive non-small-cell lung cancer (NSCLC). analyses from ARCHER 1050 evaluated efficacy in patients who did...
9.
Chan J, Siu I, Chang A, Li M, Lau R, Mok T, et al.
Ann Transl Med
. 2024 Aug;
12(4):75.
PMID: 39118957
There is a growing demand for lung parenchymal-sparing localized therapies due to the rising incidence of multifocal lung cancers and the growing number of patients who cannot undergo surgery. Lung...
10.
Saw S, Low Y, Lai G, Chan L, Wong W, Tsui G, et al.
Lung Cancer
. 2024 Jun;
193:107856.
PMID: 38889498
Objectives: First-line pemetrexed-platinum chemotherapy + osimertinib(Pem-Plat-Osi) improves progression-free survival as compared to osimertinib alone in advanced epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, many patients are hesitant...